Levofloxacin Hydrochloride Tablets

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder the replication of bacteria to achieve antibacterial effect. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, Citrobacter, Acinetobacter, and Gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and gonorrhea. It also has good antibacterial effects on some methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, hemolytic Streptococci, and Legionella, Mycoplasma, Chlamydia, etc. However, it has poor effects on anaerobic bacteria and enterococci.

The main ingredient of this product is levofloxacin hydrochloride.

This product is an off-white or light yellow tablet or film-coated tablet, which appears white or light yellow after removing the film coating.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria; respiratory system infections: acute bronchitis, chronic bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis complicated with infection, pneumonia, pharyngitis, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: prostatitis, epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic bacteria infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal) inflammation, subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid, etc.; other infections: trauma, burns and postoperative wound infection, abdominal infection (metronidazole can be used in combination when necessary), mastitis, cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Oral administration. Adults take 200mg~300mg per day, divided into 2~3 times orally. For patients with more serious conditions, the maximum daily dose can be increased to 600mg, divided into 3 times orally. In addition, the dose can be increased or decreased appropriately according to the type of infection and symptoms.

Adverse reactions may occur during the use of levofloxacin hydrochloride: Digestive system: sometimes nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, indigestion, etc.; Allergies: Occasionally edema, urticaria, fever, photosensitivity, and sometimes rash, itching, erythema, etc.; Nervous system: Occasionally tremor, numbness, visual abnormalities, tinnitus, hallucinations, drowsiness, and sometimes insomnia, dizziness, headache, etc.; Kidney: Occasionally increase in blood urea nitrogen; Liver: Transient liver function abnormalities may occur, such as increased serum transaminase and increased serum total bilirubin; Blood: Sometimes anemia, leukopenia, thrombocytopenia, and eosinophilia may occur; The incidence of the above adverse reactions is between 0.1 and 5%, which are generally tolerated and disappear quickly after the end of the course of treatment. If abnormalities are found, they should be observed carefully, and if necessary, the medication can be stopped and properly handled.

It is contraindicated for patients who are allergic to quinolones, pregnant and lactating women, and patients under 18 years of age.

Precautions for children: Not for use in patients under 18 years of age. Precautions for pregnancy and lactation: Not for use in pregnant or lactating women.

When this product is used simultaneously with antacids containing magnesium or aluminum, sucralfate, metal cations (such as iron), and zinc-containing multivitamin preparations, it will interfere with the absorption of this product by the gastrointestinal tract, causing the concentration of this drug in various systems to be significantly reduced. Therefore, the time of taking the above-mentioned drugs should be at least 2 hours before or after using this product. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. When used simultaneously with non-steroidal anti-inflammatory drugs, there is a possibility of inducing convulsions. When used simultaneously with oral hypoglycemic drugs, it may cause blood sugar disorders, including hyperglycemia and hypoglycemia. Therefore, blood sugar concentrations should be monitored during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep in a light-proof and airtight container.

Calculated as C18H20FN3O4 0.1g

24 months

Hainan Haili Pharmaceutical Co., Ltd.

• Founded in:

  1992-12-30

• Address:

  No. 9 Haili Road, Yonggui Industrial Development Zone, Xiuying District, Haikou City

• Tax NO.:

  9146000020133914XP

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view